Case Background:
This is a federal securities fraud class action lawsuit on behalf of those that purchased or otherwise acquired Bausch Health Companies Inc. (“Bausch”) (NYSE: BHC) securities between May 7, 2020 and June 8, 2023, inclusive (the “Class Period”).
The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Bausch & Lomb (“B+L”) spinoff would not result in two strong separate companies; (2) without B+L, Bausch was left overly leveraged and without the cashflow generated by B+L; (3) distribution of the B+L spinoff shares would not occur as represented; (4) the above statements omitted and/or concealed the potential damages Bausch faced from the Opt-Out Plaintiffs; (5) the spinoff was not intended to benefit Bausch shareholders but instead designed to subvert the Opt-Out Plaintiffs’ lawsuit against the company; and (6) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On November 20, 2025, the District Court granted Defendants’ Motion to Dismiss the Amended Complaint. On December 22, 2025, the Lead Plaintiffs appealed the dismissal to the United States Court of Appeals for the Third Circuit Court. The appeal is currently being briefed by the parties. This action is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.